Physician

Jeffrey Ambinder, MD

According to 2025 Medicare claims, Jeffrey Ambinder, MD (NPI: 1225142656) practices hematology/oncology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Westchester, NY. This provider's primary affiliated billing organization is NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (NPI: 1396794574; TIN: 112419534) and primary practice location at 10598-2939. Ambinder is affiliated with the ilumed, LLC (ACO ID: D0005), Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171), and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Ambinder's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 519 traditional Medicare patients, billed 249,045 HCPCS/CPT codes, and received $2,797,587 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 1,657 prescription claims across 225 beneficiaries totaling $4,555,379 in drug costs, led by Aranesp (Darbepoetin Alfa In Polysorbat). DME data shows 30 claims. Open Payments data shows 75 records totaling $2,324. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,853,387 to $4,555,379. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	391	196,373	$1,706,371
2016	539	301,706	$2,179,898
2017	548	220,944	$2,259,397
2018	700	321,396	$3,333,178
2019	656	273,283	$3,210,206
2020	539	298,353	$2,905,038
2021	571	273,822	$2,547,464
2022	557	268,621	$2,690,316
2023	533	266,076	$2,318,479
2024	519	249,045	$2,797,587

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	119	1,181	$1,853,387
2016	146	1,360	$2,158,391
2017	168	1,523	$2,240,890
2018	214	1,530	$2,320,527
2019	172	1,041	$1,671,761
2020	204	1,462	$2,342,132
2021	216	1,609	$3,209,961
2022	208	1,677	$3,232,829
2023	212	1,827	$4,326,710
2024	225	1,657	$4,555,379

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	50	$28,721
2016	N/R	99	$43,473
2017	N/R	98	$31,759
2018	23	121	$22,744
2019	23	126	$15,508
2020	N/R	102	$8,367
2021	N/R	17	$2,654
2022	N/R	N/R	N/R
2023	N/R	75	$17,182
2024	N/R	30	$856

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	450	1,990	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	479	2,273	$8
83615	Lactate dehydrogenase (enzyme) level	449	1,939	$6
84100	Phosphate level	450	1,966	$5
84550	Uric acid level, blood	453	1,980	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Aranesp	Darbepoetin Alfa In Polysorbat	125	2,625	$466,894
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	29	822	$380,005
Brukinsa	Zanubrutinib	29	870	$314,773
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	14	392	$290,430
Revlimid	Lenalidomide	15	420	$260,251

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$706
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	75	$2,324	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey Ambinder, MD?

Tedicare shows public-source Medicare data for Jeffrey Ambinder, MD (NPI 1225142656), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey Ambinder, MD have ACO affiliation data?

Jeffrey Ambinder, MD is shown with ACO affiliation data for ilumed, LLC (REACH, ACO ID D0005), Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171), and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Jeffrey Ambinder, MD?

Jeffrey Ambinder, MD is linked to NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (billing NPI 1396794574) in the available physician profile data.

Does Jeffrey Ambinder, MD have Open Payments data?

Jeffrey Ambinder, MD has 75 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.